FDA will no longer require Genzyme to continue the Risk Evaluation and Mitigation Strategy program.
Rare Disease Report Staff
Advertisement
Articles by Rare Disease Report Staff
Caregivers give thoughts on attributes they are looking for in DMD treatment.
FDA updates guidelines to expedite the development and review of new drugs.
Advertisement
Latest Updated Articles
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential BiomarkersPublished: June 12th 2025 | Updated: June 16th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting MembersPublished: June 10th 2025 | Updated: June 12th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular CarePublished: June 2nd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment LandscapePublished: June 3rd 2025 | Updated: June 11th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201Published: May 30th 2025 | Updated: June 5th 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across BordersPublished: April 18th 2025 | Updated: April 21st 2025
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
2
Effectively Managing Immunizations in the Long-Term Care Setting
3
NCCN Guideline Update in SCLC Adds Maintenance Lurbinectedin, Removes Chemotherapy-Free Interval
4
New Teclistamab Study in Multiple Myeloma Shows Improved Tolerance, Responses
5
